We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Theravance's Q1 Loss Wider Than Expected, Revenues Rise Y/Y
Read MoreHide Full Article
Theravance Biopharma (TBPH - Free Report) reported first-quarter 2025 adjusted net loss of 17 cents per share, which was wider than the Zacks Consensus Estimate of a loss of 11 cents. In the year-ago quarter, the company had reported an adjusted loss of 9 cents per share.
The reported loss excludes share-based compensation expense, income tax benefit and non-cash interest expense. Including these items, the company incurred a loss of 27 cents per share in the first quarter compared with a loss of 24 cents in the year-ago quarter. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.)
Total revenues in the first quarter came in at $15.4 million, also missing the Zacks Consensus Estimate of $16 million. Revenues, however, rose 6.2% year over year owing to increased collaboration revenues from partner Viatris (VTRS - Free Report) .
Year to date, shares of Theravance have risen 5.2% against the industry’s decline of 3.1%.
Image Source: Zacks Investment Research
TBPH's Q1 Results in Detail
The top line fully comprised Viatris’ collaboration revenues in relation to Yupelri (revefenacin) sales.
Theravance and Viatris have collaborated for the development and commercialization of Yupelri, which is approved in the United States for the maintenance treatment of patients with chronic obstructive pulmonary disease.
Viatris and Theravance share U.S. profits and losses received in connection with the commercialization of Yupelri. While Viatris gets 65% of the profits, Theravance receives 35%. Viatris' collaboration revenues include Theravance’s 35% share of net sales of Yupelri, as well as its proportionate amount of the total shared costs incurred by the two companies.
VTRS recognizes product sales from Yupelri and also owns a stake in Theravance. Viatris recorded $58.3 million in U.S. net sales of Yupelri in the first quarter, up 6% year over year.
Theravance has some royalty interest in GSK plc’s (GSK - Free Report) chronic obstructive pulmonary disease (COPD) medicine, Trelegy Ellipta.
In February 2025, TBPH earned a $50 million milestone payment from partner Royalty Pharma based on Trelegy Ellipta’s net sales of $3.46 billion in 2024, as reported by GSK.
TBPH is entitled to receive a similar milestone payment of $50 million from partner Royalty Pharma if Trelegy Ellipta’s global net sales total ~$3.41 billion in 2025. In 2022, Theravance sold its economic interest in sales-based royalty rights on worldwide net sales of GSK’s Trelegy to Royalty Pharma while retaining some rights to certain future milestone payments.
Research and development expenses (excluding share-based compensation) totaled $10.4 million, up almost 40.5% from the year-ago quarter’s level. Selling, general and administrative expenses (excluding share-based compensation) increased around 13.2% year over year to $14.6 million.
As of March 31, 2025, Theravance had cash, cash equivalents and marketable securities worth $130.9 million compared with $88.4 million as of Dec. 31, 2024.
TBPH's 2025 Financial Guidance
Theravance reaffirmed its financial guidance for 2025.
The company continues to expect adjusted R&D expenses (excluding share-based compensation) in the $32-$38 million range in 2025. Adjusted SG&A expenses (excluding share-based compensation) are projected between $50 million and $60 million.
Theravance continues to expect share-based compensation expenses of $18-$20 million in 2025.
TBPH expects both adjusted losses and cash burn in 2025 to be similar to 2024 levels.
TBPH's Pipeline & Other Updates
Theravance is developing an investigational candidate, ampreloxetine, a norepinephrine reuptake inhibitor for the treatment of symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA), a progressive brain disorder.
The phase III CYPRESS study is evaluating ampreloxetine for nOH MSA. The CYPRESS study is expected to complete patient enrollment by late summer. Top-line data from the same is expected six months after enrollment is completed. TBPH plans to submit a new drug application (NDA) for ampreloxetine if the study data are found to be positive.
Theravance Biopharma, Inc. Price, Consensus and EPS Surprise
In the past 60 days, estimates for ANI Pharmaceuticals’ earnings per share have increased from $6.30 to $6.36 for 2025. During the same time, earnings per share estimates for 2026 have increased from $6.85 to $7.14. Year to date, shares of ANIP have rallied 29.4%.
ANIP’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 17.32%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Theravance's Q1 Loss Wider Than Expected, Revenues Rise Y/Y
Theravance Biopharma (TBPH - Free Report) reported first-quarter 2025 adjusted net loss of 17 cents per share, which was wider than the Zacks Consensus Estimate of a loss of 11 cents. In the year-ago quarter, the company had reported an adjusted loss of 9 cents per share.
The reported loss excludes share-based compensation expense, income tax benefit and non-cash interest expense. Including these items, the company incurred a loss of 27 cents per share in the first quarter compared with a loss of 24 cents in the year-ago quarter. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.)
Total revenues in the first quarter came in at $15.4 million, also missing the Zacks Consensus Estimate of $16 million. Revenues, however, rose 6.2% year over year owing to increased collaboration revenues from partner Viatris (VTRS - Free Report) .
Year to date, shares of Theravance have risen 5.2% against the industry’s decline of 3.1%.
Image Source: Zacks Investment Research
TBPH's Q1 Results in Detail
The top line fully comprised Viatris’ collaboration revenues in relation to Yupelri (revefenacin) sales.
Theravance and Viatris have collaborated for the development and commercialization of Yupelri, which is approved in the United States for the maintenance treatment of patients with chronic obstructive pulmonary disease.
Viatris and Theravance share U.S. profits and losses received in connection with the commercialization of Yupelri. While Viatris gets 65% of the profits, Theravance receives 35%. Viatris' collaboration revenues include Theravance’s 35% share of net sales of Yupelri, as well as its proportionate amount of the total shared costs incurred by the two companies.
VTRS recognizes product sales from Yupelri and also owns a stake in Theravance. Viatris recorded $58.3 million in U.S. net sales of Yupelri in the first quarter, up 6% year over year.
Theravance has some royalty interest in GSK plc’s (GSK - Free Report) chronic obstructive pulmonary disease (COPD) medicine, Trelegy Ellipta.
In February 2025, TBPH earned a $50 million milestone payment from partner Royalty Pharma based on Trelegy Ellipta’s net sales of $3.46 billion in 2024, as reported by GSK.
TBPH is entitled to receive a similar milestone payment of $50 million from partner Royalty Pharma if Trelegy Ellipta’s global net sales total ~$3.41 billion in 2025. In 2022, Theravance sold its economic interest in sales-based royalty rights on worldwide net sales of GSK’s Trelegy to Royalty Pharma while retaining some rights to certain future milestone payments.
Research and development expenses (excluding share-based compensation) totaled $10.4 million, up almost 40.5% from the year-ago quarter’s level. Selling, general and administrative expenses (excluding share-based compensation) increased around 13.2% year over year to $14.6 million.
As of March 31, 2025, Theravance had cash, cash equivalents and marketable securities worth $130.9 million compared with $88.4 million as of Dec. 31, 2024.
TBPH's 2025 Financial Guidance
Theravance reaffirmed its financial guidance for 2025.
The company continues to expect adjusted R&D expenses (excluding share-based compensation) in the $32-$38 million range in 2025. Adjusted SG&A expenses (excluding share-based compensation) are projected between $50 million and $60 million.
Theravance continues to expect share-based compensation expenses of $18-$20 million in 2025.
TBPH expects both adjusted losses and cash burn in 2025 to be similar to 2024 levels.
TBPH's Pipeline & Other Updates
Theravance is developing an investigational candidate, ampreloxetine, a norepinephrine reuptake inhibitor for the treatment of symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA), a progressive brain disorder.
The phase III CYPRESS study is evaluating ampreloxetine for nOH MSA. The CYPRESS study is expected to complete patient enrollment by late summer. Top-line data from the same is expected six months after enrollment is completed. TBPH plans to submit a new drug application (NDA) for ampreloxetine if the study data are found to be positive.
Theravance Biopharma, Inc. Price, Consensus and EPS Surprise
Theravance Biopharma, Inc. price-consensus-eps-surprise-chart | Theravance Biopharma, Inc. Quote
TBPH's Zacks Rank & Stock to Consider
Theravance currently carries a Zacks Rank #3 (Hold).
A better-ranked stock in the biotech sector is ANI Pharmaceuticals, Inc. (ANIP - Free Report) , carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
In the past 60 days, estimates for ANI Pharmaceuticals’ earnings per share have increased from $6.30 to $6.36 for 2025. During the same time, earnings per share estimates for 2026 have increased from $6.85 to $7.14. Year to date, shares of ANIP have rallied 29.4%.
ANIP’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 17.32%.